focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 16.50
High: 16.50
Low: 16.50
Prev. Close: 16.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Mar 2023 10:31

RNS Number : 0102S
Destiny Pharma PLC
06 March 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Destiny Pharma Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Unicorn Asset Management Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Unicorn AIM VCT plc

City and country of registered office (if applicable)

Newton Abbot, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

01 March 2023

6. Date on which issuer notified (DD/MM/YYYY):

03 March 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

4.65%

4.65%

4,076,923

Position of previous notification (if

applicable)

5.14%

5.14%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares

GB00BDHSP575

4,076,923

4.65%

SUBTOTAL 8. A

4,076,923

4.65%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Figures are based on total voting rights of 87,742,819

 

Place of completion

Unicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU

Date of completion

03 March 2023

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAEDKEDEDEFA
Date   Source Headline
1st Dec 20205:23 pmRNSHolding(s) in Company
30th Nov 20202:00 pmRNSHolding(s) in Company
26th Nov 202010:50 amRNSResult of General Meeting and Total Voting Rights
25th Nov 20207:00 amRNSResult of Open Offer
9th Nov 20204:25 pmRNSFundraising and Acquisition
12th Oct 20207:00 amRNSClinical Study Patient Recruitment Update
17th Sep 20207:00 amRNSInterim results for the 6 months ended 30 Jun 2020
17th Sep 20207:00 amRNSUpdate on Phase 2b clinical study of XF-73
10th Sep 20207:00 amRNSNotice of Results
7th Sep 20204:40 pmRNSSecond Price Monitoring Extn
7th Sep 20204:35 pmRNSPrice Monitoring Extension
7th Sep 20202:06 pmRNSSecond Price Monitoring Extn
7th Sep 20202:01 pmRNSPrice Monitoring Extension
7th Sep 202011:06 amRNSSecond Price Monitoring Extn
7th Sep 202011:01 amRNSPrice Monitoring Extension
7th Sep 20209:05 amRNSSecond Price Monitoring Extn
7th Sep 20209:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSCollaboration to co-develop treatment for COVID-19
11th Aug 20207:00 amRNSPositive interim safety review of XF-73 phase 2b
27th Jul 20207:00 amRNSUpdate on Phase 2b clinical study of XF-73
15th Jul 20207:00 amRNSDestiny Pharma notes launch of AMR Action Fund
19th Jun 202011:00 amRNSCancellation and Grant of Options
10th Jun 202012:30 pmRNSResult of AGM
9th Jun 20207:00 amRNSGrant awarded for Cardiff University collaboration
12th May 20203:15 pmRNSPosting of Annual Report and Notice of AGM
4th May 20207:00 amRNSIndependent review supports the potential of XF-73
29th Apr 20207:00 amRNSFinal Results
24th Apr 20207:00 amRNSNotice of Results
3rd Mar 20207:00 amRNSClinical and Business Update
20th Jan 20207:00 amRNSUpdate on the development of XF drug formulations
17th Dec 20197:00 amRNSAPSIC guidelines recommend decolonising S. aureus
2nd Dec 20197:00 amRNSDirectorate Change
2nd Dec 20197:00 amRNSDestiny to present at UK-China AMR Workshop
15th Nov 20197:30 amRNSPresentation at the Investival Showcase
6th Nov 20197:00 amRNSDestiny Pharma to present at World AMR Congress
16th Oct 20197:00 amRNSPositive phase 1 results published in journal
23rd Sep 20197:00 amRNSDirectorate Change
23rd Sep 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
12th Sep 20197:00 amRNSNotice of Results
10th Sep 20197:00 amRNSUniversity of Sheffield Research Collaboration
2nd Sep 20197:00 amRNSXF Drug platform data presented at EuroBiofilms
15th Aug 201912:20 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSPresentation at Gordon Research Conference
19th Jul 20193:12 pmRNSHolding(s) in Company
4th Jun 20192:39 pmRNSGrant of Options
4th Jun 201912:06 pmRNSResult of AGM
9th May 20192:06 pmRNSAppointment of NOMAD and Joint Broker
29th Apr 20192:28 pmRNSPosting of Annual Report and Notice of AGM
9th Apr 20197:00 amRNSFinal Results
5th Apr 20195:06 pmRNSExercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.